Brief: Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
08/04/2026 13:14
April 8 (Reuters) - Radiopharm Theranostics Ltd RAD.AX: RADIOPHARM THERANOSTICS ADVANCES TO COHORT 3 IN 177LU-RAD202 PHASE 1 DOSE ESCALATING CLINICAL TRIAL RADIOPHARM THERANOSTICS LTD: ON TRACK TO COMPLETE PHASE 1 DOSE ESCALATION BY END OF 2026 Source text: ID:nGNX4XZMwX Further company coverage: RAD.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Radiopharm Theranostics
See all newsNASDAQ RESUMED AT 09:47 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:42 AM
Brief: Radiopharm Theranostics To Meet With U.S. FDA To Align On Pivotal Phase 3 Trial Design For Rad 101 In Diagnosis Of Brain Metastases
NASDAQ RESUMED AT 09:56 AM
NASDAQ TRADE HALT CONTINUES VOLATILITY TRADING PAUSE AT 09:50 AM